Cizzle Biotechnology Holdings PLC Notice of Annual General Meeting

RNS Number : 7441Q

Cizzle Biotechnology Holdings PLC

03 June 2024

 

Cizzle Biotechnology Holdings plc

("Cizzle Biotechnology", or the "Company")

Notice of Annual General Meeting

 

Cizzle Biotechnology, the UK based diagnostics developer, announces that the notice of Annual General Meeting ("AGM"), has been sent to shareholders and is available for viewing on the Company's website at https://cizzlebiotechnology.com.

 

The AGM will be held at 11.00 a.m. on 24 June 2024 at the offices of Shakespeare Martineau LLP, 6^th Floor, 60 Gracechurch Street, London, EC3V 0HR.

 

Enquiries:

 

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

 

Allenby Capital Limited		[phone]
John Depasquale
George Payne

 

Novum Securities Limited	[phone]
Colin Rowbury Jon Bellis

 

IFC Advisory Limited	[phone]
Tim Metcalfe
Florence Chandler

 

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test to facilitate the early detection of lung cancer based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant has been shown to be highly correlated with early-stage lung cancer.  The Company's proprietary technology results from the work of Professor Coverley and colleagues at the University of York.

For more information please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NOAQKDBBNBKDPAK